levofloxacin has been researched along with rimantadine in 4 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (rimantadine) | Trials (rimantadine) | Recent Studies (post-2010) (rimantadine) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 651 | 47 | 138 |
| Protein | Taxonomy | levofloxacin (IC50) | rimantadine (IC50) |
|---|---|---|---|
| Solute carrier family 22 member 2 | Homo sapiens (human) | 4.4 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 7.3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Giacomini, KM; Huang, Y; Khuri, N; Kido, Y; Kosaka, A; Morrissey, KM; Sali, A; Wittwer, MB; Zhang, X; Zur, AA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Kalra, S; Khatik, GL; Kumar, GN; Kumar, R; Narang, R; Nayak, SK; Singh, SK; Sudhakar, K | 1 |
2 review(s) available for levofloxacin and rimantadine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Recent advancements in mechanistic studies and structure activity relationship of F
Topics: Animals; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium; Proton-Translocating ATPases; Structure-Activity Relationship | 2019 |
2 other study(ies) available for levofloxacin and rimantadine
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
Topics: Computer Simulation; Fluorescent Dyes; Organic Cation Transport Proteins; Prescription Drugs | 2013 |